Monopar Therapeutics Inc. (NASDAQ:MNPR) Receives $106.20 Consensus Target Price from Brokerages

Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR) have been assigned an average rating of “Buy” from the fourteen research firms that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, eleven have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average twelve-month price target among analysts that have issued a report on the stock in the last year is $107.00.

MNPR has been the topic of several recent research reports. Jones Trading upgraded shares of Monopar Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Friday, October 10th. Barclays set a $125.00 price objective on shares of Monopar Therapeutics and gave the company an “overweight” rating in a research note on Monday, October 13th. Cantor Fitzgerald restated an “overweight” rating on shares of Monopar Therapeutics in a report on Wednesday, September 24th. Morgan Stanley initiated coverage on Monopar Therapeutics in a research report on Friday, January 9th. They set an “overweight” rating and a $115.00 target price on the stock. Finally, Leerink Partners initiated coverage on Monopar Therapeutics in a research note on Monday, November 10th. They set an “outperform” rating and a $115.00 price objective for the company.

Insider Activity at Monopar Therapeutics

In other news, CFO Quan Anh Vu bought 1,500 shares of the firm’s stock in a transaction that occurred on Friday, December 26th. The stock was bought at an average price of $69.95 per share, with a total value of $104,925.00. Following the completion of the transaction, the chief financial officer directly owned 1,500 shares of the company’s stock, valued at approximately $104,925. The trade was a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 20.50% of the stock is currently owned by company insiders.

Institutional Trading of Monopar Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in MNPR. Goldman Sachs Group Inc. purchased a new position in Monopar Therapeutics during the 1st quarter worth $673,000. Jane Street Group LLC purchased a new stake in shares of Monopar Therapeutics during the first quarter worth about $377,000. AlphaQuest LLC increased its holdings in shares of Monopar Therapeutics by 46.8% during the second quarter. AlphaQuest LLC now owns 1,784 shares of the company’s stock valued at $64,000 after acquiring an additional 569 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Monopar Therapeutics by 99.7% in the 2nd quarter. Geode Capital Management LLC now owns 96,919 shares of the company’s stock valued at $3,468,000 after purchasing an additional 48,379 shares during the last quarter. Finally, Police & Firemen s Retirement System of New Jersey purchased a new stake in Monopar Therapeutics during the 2nd quarter worth approximately $34,000. Hedge funds and other institutional investors own 1.83% of the company’s stock.

Monopar Therapeutics Stock Performance

Shares of NASDAQ MNPR opened at $69.07 on Friday. The stock has a 50 day moving average price of $74.84 and a 200 day moving average price of $62.98. The firm has a market capitalization of $461.39 million, a price-to-earnings ratio of -20.08 and a beta of 1.46. Monopar Therapeutics has a 52-week low of $26.06 and a 52-week high of $105.00.

Monopar Therapeutics (NASDAQ:MNPR) last issued its earnings results on Thursday, November 13th. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.02). Analysts forecast that Monopar Therapeutics will post -1.65 earnings per share for the current year.

About Monopar Therapeutics

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.